Abstract:Elicitation of antibodies with potent and broad neutralizing activity against HIV by immunization remains a challenge. Several monoclonal antibodies (mAbs) isolated from humans with HIV-1 infection exhibit such activity but vaccine immunogens based on structures containing their epitopes have not been successful for their elicitation. All known broadly neutralizing mAbs (bnmAbs) are immunoglobulin (Ig) Gs (IgGs) and highly somatically hypermutated which could impede their elicitation. Ig Ms (IgMs) are on average significantly less divergent from germline antibodies and are relevant for the development of vaccine immunogens but are underexplored compared to IgGs. Here we describe the identification and characterization of several human IgM-derived mAbs against HIV-1 which were selected from a large phage-displayed naive human antibody library constructed from blood, lymph nodes and spleens of 59 healthy donors. These antibodies bound with high affinity to recombinant envelope glycoproteins (gp140s, Envs) of HIV-1 isolates from different clades. They enhanced or did not neutralize infection by some of the HIV-1 primary isolates using CCR5 as a coreceptor but neutralized all CXCR4 isolates tested although weakly. One of these antibodies with relatively low degree of somatic hypermutation was more extensively characterized. It bound to a highly conserved region partially overlapping with the coreceptor binding site and close to but not overlapping with the CD4 binding site. These results suggest the existence of conserved structures that could direct the immune response to non-neutralizing or even enhancing antibodies which may represent a strategy used by the virus to escape neutralizing immune responses. Further studies will show whether such a strategy plays a role in HIV infection of humans, how important that role could be, and what the mechanisms of infection enhancement are. The newly identified mAbs could be used as reagents to further characterize conserved non-neutralizing, weakly neutralizing or enhancing epitopes and modify or remove them from candidate vaccine immunogens.

VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

E108 Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

Antibody‐virus Co‐evolution in HIV Infection: Paths for HIV Vaccine Development

Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor.

Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies.

HIV-1 Antibodies from Infection and Vaccination: Insights for Guiding Vaccine Design

A VH1-69 Antibody Lineage from an Infected Chinese Donor Potently Neutralizes HIV-1 by Targeting the V3 Glycan Supersite.

Recognition Of Synthetic Glycopeptides By Hiv-1 Broadly Neutralizing Antibodies And Their Unmutated Ancestors

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies

Affinity Maturation In An Hiv Broadly Neutralizing B-Cell Lineage Through Reorientation Of Variable Domains

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Cross-Reactive Human Igm-Derived Monoclonal Antibodies That Bind to Hiv-1 Envelope Glycoproteins

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

Autoreactivity and Broad Neutralization of Antibodies Against HIV-1 Are Governed by Distinct Mutations: Implications for Vaccine Design Strategies

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Hierarchical sequence-affinity landscapes shape the evolution of breadth in an anti-influenza receptor binding site antibody